-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 NQWgTAj9+bl9kWMhnI8sMFG489Wudy3twbmepCVMlLqqkFAdHnIqFpnukcqjWbZK
 Wu1CEiqZSdx5wFqg6MmvJA==

<SEC-DOCUMENT>0001193125-05-030078.txt : 20050215
<SEC-HEADER>0001193125-05-030078.hdr.sgml : 20050215
<ACCEPTANCE-DATETIME>20050215100742
ACCESSION NUMBER:		0001193125-05-030078
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20050215
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20050215
DATE AS OF CHANGE:		20050215

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CRYO CELL INTERNATIONAL INC
		CENTRAL INDEX KEY:			0000862692
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-SERVICES, NEC [8900]
		IRS NUMBER:				223023093
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1130

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23386
		FILM NUMBER:		05615031

	BUSINESS ADDRESS:	
		STREET 1:		3165 MCMULLEN BOOTH RD
		STREET 2:		BLDG B
		CITY:			CLEARWATER
		STATE:			FL
		ZIP:			33761
		BUSINESS PHONE:		7277230333

	MAIL ADDRESS:	
		STREET 1:		3165 MCMULLEN BOOTH RD
		STREET 2:		BLDG. B
		CITY:			CLEARWATER
		STATE:			FL
		ZIP:			33761
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<HR SIZE="3" NOSHADE COLOR="#000000" ALIGN="left"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><HR WIDTH="17%" SIZE="1" NOSHADE
COLOR="#000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>FORM 8-K </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><HR WIDTH="17%" SIZE="1" NOSHADE COLOR="#000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="3"><B>Pursuant to Section 13 or 15(d) of </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>the Securities Exchange Act of 1934 </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Date of Report (Date of earliest event reported): February 15, 2005
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><HR WIDTH="17%" SIZE="1" NOSHADE COLOR="#000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="6"><B>CRYO-CELL International, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Exact
name of registrant as specified in its charter) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><HR WIDTH="17%" SIZE="1" NOSHADE COLOR="#000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>0-23386</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>22-3023093</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(State or other jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="1"><B>of incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Commission File Number)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>700 Brooker Creek Blvd., Suite 1800, Oldsmar, FL</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>34677</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Address of principal executive offices)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Registrant&#146;s
telephone number, including area code: (813) 749-2100 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="2"><B>Not applicable </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Former name or former address, if changed since last report) </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><HR WIDTH="17%" SIZE="1" NOSHADE COLOR="#000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P><HR SIZE="3" NOSHADE COLOR="#000000" ALIGN="left">

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Item 2.02. Results of Operations and Financial Condition. </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The information in this Item is furnished to, but not filed with, the
Securities and Exchange Commission (the &#147;Commission&#148;) solely under Item 12 of Form 8-K, &#147;Results of Operations and Financial Condition.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">On February 11, 2005, CRYO-CELL International, Inc. issued a press release that included financial information for the twelve months ended November 30,
2004. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Item 9.01. Financial Statements and Exhibits. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><U>Exhibits</U><B></B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Press Release dated February 11, 2005.</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">-2- </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>SIGNATURE </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0">

<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">CRYO-CELL INTERNATIONAL, INC.</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">(Registrant)</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Date: February 15, 2005</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">By:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">/s/ Jill M. Taymans</FONT></P><HR SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Name:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Jill M. Taymans</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Title:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Vice President, Finance</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">-3- </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><U>EXHIBIT INDEX </U></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>EXHIBIT</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="1"><B>NUMBER</B></FONT></P><HR WIDTH="56" SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"><B>EXHIBIT</B></FONT></P><HR WIDTH="53" SIZE="1" NOSHADE ALIGN="left" COLOR="#000000"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Press Release dated February 11, 2005.</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">-4- </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">

<IMG SRC="g73132cryo-cell.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="44%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2"><B>For&nbsp;Immediate&nbsp;Release</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2"><B>Contact:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2"><B>Todd Atenhan</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">813-749-2100</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">813-855-4745 (Fax)</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2"><B>investor.relations@CRYO-CELL.com</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>CRYO-CELL
INTERNATIONAL, INC. REPORTS RESULTS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>FOR FISCAL 2004 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Company Reports Net Income, Increased Revenues, Higher Gross Margins, </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>and Strong Cash Position </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B><I>SOLID FINANCIAL PERFORMANCE CONTINUES AS COMPANY PROCEEDS WITH STRATEGIC PLAN </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Clearwater, FL &#150; February 11, 2005 </B>- CRYO-CELL International, Inc. (OTC Bulletin Board Symbol: CCEL) (the &#147;Company&#148;)
today announced revenues of approximately $12.2 million for the fiscal year ended November 30, 2004, compared to approximately $7.5 million for fiscal 2003. The 62% revenue increase over 2003 period is primarily attributable to new clients and the
effects of successfully implemented price increases during 2004 for newly enrolling clients. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">Net income in fiscal 2004 was approximately $2.8 million, or $0.25 per common share - basic, compared to a net loss of approximately $7.5 million, or ($0.66) per common share - basic, in fiscal 2003. The net income in
2004, compared to the net loss in 2003, was due in part to a $4.1 million increase in gross profits compared to 2003 levels and a reduction of $1.7 million, or 21% in marketing, general and administrative expenses. Net income in 2004 also included
approximately $1.1 million from the reversal of an accrual of expense in fiscal 2003 relating to the PharmaStem litigation. That accrual had increased the net loss in fiscal 2003 by $1.1 million. The reversal of the accrual resulted from a favorable
ruling by the Court on post trial motions in that case during 2004. Other items that contributed to the net loss in fiscal 2003 that are not included in the results of fiscal 2004 include asset impairment charges of approximately $2 million. The
impairment charges in 2003 included the reduction in value of investments in subsidiaries and affiliates and charges related to the decision to discontinue further investment in and utilization of the Company&#146;s proprietary storage technology.
In addition, losses from discontinued operations of Stem Cell Preservation Technologies, Inc., a discontinued subsidiary, were approximately $93,000 in 2004 compared with $689,000 in 2003. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The Company also recognized approximately $550,000 in other income in 2004, compared to
approximately $211,000 in 2003. Other income principally consisted of income recognized on the sale of license agreements, royalty income earned on the subsequent processing and storage of specimens in geographic areas where the Company has
licensing agreements and from the sale of sub-licenses by licensees. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The Company&#146;s gross margin increased to 74% of revenue in 2004 from 65% in 2003. The gross margin improvement is a
result of the 62% increase in revenues, as described above, combined with an increase of only 20% in cost of sales. As of November 30, 2004, the Company had approximately $6.0 million in available cash, cash equivalents and marketable securities and
no long-term debt. As a result of the Court&#146;s favorable ruling in the PharmaStem litigation, the Company recovered approximately $958,000 in cash during the fourth quarter 2004 that was being held in an escrow account in connection with the
original jury verdict. During fiscal 2004, the Company invested approximately $686,000 of capital in the build-out of its new facility, which was funded entirely from cash flow from operations. <B></B> </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">&#147;We are very pleased with CRYO-CELL&#146;s continuing solid performance throughout
2004,&#148; commented Mercedes Walton, Chairman and interim CEO. &#147;The Company achieved significant operational milestones as reflected by increased revenues, decreased expense, higher margins, positive operating income and enhanced shareholder
value. From a strategic perspective, CRYO-CELL made substantial progress in 2004 towards reaching resolution on a majority of outstanding legacy issues, along with launching key alliances that we believe will accelerate our industry leadership
moving forward.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In addition to successfully repositioning
CRYO-CELL&#146;s core service which included a strategic pricing increase, the Company was awarded category exclusivity to participate in a highly targeted marketing initiative with American Baby and Prenate Elite<FONT FACE="Times New Roman"
SIZE="1" COLOR="#000000"><SUP>&#153;<FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"></FONT></SUP><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"></FONT></FONT>, America&#146;s most widely prescribed prenatal vitamin. CRYO-CELL also
joined some of America&#146;s leading companies in teaming up with Upromise&reg;, Inc. to become the first and only private cord blood bank to participate in this industry-leading college savings service in which the Company gives clients money back
for college. CRYO-CELL also signed a License and Royalty Agreement with Asia CRYO-CELL Private Limited, a newly formed Indian company that is well capitalized and has demonstrated skills, knowledge and professional networks necessary to successfully
launch the U-Cord&reg; program in India, with approximately 20 million births per year representing one of the largest birth markets in the world. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In another major milestone, CRYO-CELL relocated its corporate headquarters in November 2004 to a newly constructed, nearly 18,000 square-foot, state-of-the-art, current
Good Manufacturing Practice and Good Tissue Practice (cGMP/cGTP)-compliant facility. The highly secured, technologically advanced facility is designed to support the expansive and growing base of currently more than 75,000 CRYO-CELL clients, over
the next ten years. The Company&#146;s new laboratory processing facility boasts a class 10,000 clean room and class 100 environments for the processing of cord blood stem cells and other cellular tissues. The Company believes that CRYO-CELL is the
first private bank to process cord blood in a technologically and operationally advanced (cGMP/cGTP)-compliant facility, which positions CRYO-CELL well in the market and ahead of emerging regulation. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">&#147;Moving forward, CRYO-CELL expects to build on our strong performance, formidable
progress and continuing momentum of 2004,&#148; Ms. Walton continued. &#147;With a strong cash position and no long-term debt, we anticipate that continued revenue growth and further advancements with our strategic plan and business goals will
favorably impact earnings in the coming periods.&#148; </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2">About CRYO-CELL International, Inc. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Based in Oldsmar, Florida, CRYO-CELL is the world&#146;s largest U-Cord<FONT
FACE="Times New Roman" SIZE="1" COLOR="#000000"><SUP>&reg;<FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"></FONT></SUP><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"></FONT></FONT> stem cell banking firm, offering high-quality cord
blood preservation exclusively for the benefit of newborn babies and possibly other members of their family. With over 75,000 clients, CRYO-CELL is accredited by the American Association of Blood Banks (AABB) and operates in a newly constructed
state-of-the-art current Good Manufacturing Practice and Good Tissue Practice (cGMP/cGTP)-compliant facility.. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">CRYO-CELL is a publicly traded company. OTC Bulletin Board Symbol CCEL. Expectant parents or healthcare professionals may call 1-800-STOR-CELL (1-800-786-7235) or visit www.CRYO-CELL.com. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Forward-Looking Statement </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Statements wherein the terms &#147;believes&#148;, &#147;intends&#148;, &#147;projects&#148;
or &#147;expects&#148; as used are intended to reflect &#147;forward-looking statements&#148; of the Company. The information contained herein is subject to various risks, uncertainties and other factors that could cause actual results to differ
materially from the results anticipated in such forward-looking statements or paragraphs, many of which are outside the control of the Company. These uncertainties and other factors include any adverse effect or limitations caused by recent
increases in government regulation of stem cell storage facilities; any increased competition in our business; any decrease or slowdown in the number of people seeking to store umbilical cord blood stem cells or decrease in the number of people
paying annual storage fees; any adverse impacts on our revenue or operating margins due to the costs associated with increased growth in our business, including the possibility of unanticipated costs relating to the operation of our new facility;
any technological breakthrough or medical breakthrough that would render the Company&#146;s business of stem cell preservation obsolete; any material failure or malfunction in our storage facilities; any natural disaster such as a tornado, other
disaster (fire) or act of terrorism that adversely affects stored specimens; the costs associated with defending or prosecuting litigation matters and any material adverse result from such matters; decreases in asset valuations; any continued
negative effect from adverse publicity in the past year regarding the Company&#146;s business operations; any negative consequences resulting from deriving, shipping and storing specimens at a second location; any negative effect from the filed
class action shareholder lawsuits; and other risks and uncertainties. The foregoing list is not exhaustive, and the Company disclaims any obligations to subsequently revise any forward-looking statements to reflect events or circumstances after the
date of such statements. Readers should carefully review the risk factors described in other documents the Company files from time to time with the Securities and Exchange Commission, including the most recent Annual Report on Form 10-KSB, Quarterly
Reports on Form 10-QSB and any Current Reports on Form 8-K filed by the Company. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2">-END- </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g73132cryo-cell.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g73132cryo-cell.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`1@*H`P$1``(1`0,1`?_$`*D``0``!@,!`0``````
M```````!!@<("0H"!`4+`P$!`0$!`0$```````````````$$`@,%$```!@$#
M`@,%!0,(!0<-```!`@,$!08'`!$($@DA$Q@Q%%;6ET%1(A4688$*<9&AP7(C
M%QHR0K,D&?"Q,W,T=%CQ4D.4M"4V1K;&*7DZ$0$``@$"!@(!!0``````````
M`0(1(4$Q47$R`Q,2,\%AT2)B@O_:``P#`0`"$0,1`#\`W]%-^D-M]]P]@[#]
MO_+^71U3&=>#1DYX_P`3IS:XL\T>3_&^BX4XWS]-PGF&T8]K4U:&F0#6*2B8
M0[<K=U,FC+>R8&?'%40.*2*9!V#8NIEHCQTM$3,<86G?YN_N"_\`A]XHAX@'
MBSR=[1$`#_YY]HB.F5]5.3A_F\^X'L!O3]Q2$AE10*K[CE#R#K`&_E$7_7'D
MG5$/84#"8?NTR>JG)S_S=_<%_P##[Q1_]3R:(?N$+SL.F3U4Y(#_`!>'<$#I
MWX^\4@*)TRF$K+)HF`IE"E-T@-Y`!/TB.V_AO[='-_'2*S,<</H3T>8=V*GU
M6Q/B))/)ZLU^9=(MP,#9%S)Q+1\X2;=9SJ^019P(%ZA$W3MN(ZK,F;S4]]NH
M-]S!MX[B)1V,`!MXB`CH.1CE+_I&`N_LW';?V>S?V^(Z!UE\/Q!X@(A^T`#<
M1T#K+N(;^S;[!V\=_8.VPCX?9H(B8H>`B`#]WV_S>W00`Q1WV'V"(#[?`0VW
M#^G0<163`0*)MC".P!L;<1^X`V\?9H.0'*(`(#N`_:`"(?O$`\/WZ"("`[[#
MOM_Y/W^(:".@@(@&VX[;^S]H_<'WCH`&`1$`WW#;?P'[?9]GC_5H("<H"!1'
M81#</`?9N4OMVV#Q,&@=9?9U!]H^W[`'81_D`=!`5"`(@)O$!V$-AW`=A'[O
MM`-_VAH(]9?O_P"7]>^@B)BA[3`'\HA_+H(`<AO88!V'I_?L`[?S#H.7M_I_
MH\!_IT#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0<"
MJ$,4#E$3%$=@$"F'?]H`!=]O#V^S00%9,!('5XJ#L38IAZAV$WM`!`/PAO\`
MR:`95,FW6<I`$-P$P])=AWV_$.P?9H.*;A!8O6DLFJGU"7S$SE.3J*(@8O64
M1+N40V'Q\!]N@Y^838!Z@V$!$!^P0#V^/L\-!UE9!@@X;M%GC5%T\.=-FV57
M337=J)IF55(U2.8IW!TDB"8P$`PE*`B.P!H.P*J8#L)@`?`/'</$P[`']H1^
MSVZ`*R9>L3'`H)E$ZAC;E*0A0W$QCB`%`H`'MW]F@_)!XT=)%7:N4'*!]^A9
MNJ1=$W2/2/2JD)R#L/[=!^HJD`-Q-X>'V#]H;_=]P^/W:#K-I&/>>?[F]:N_
M=ESM7/NRZ:_N[I("F4:K^48_DN4RF`3)FV.4!#<-!^Q738PF`KA$PD+UG`JA
M#"0@&$HG.`"(E(!@'<1\`VT'!H^9/VR3Q@[;/6:W4*+MFNDY;*@4QB&%-PB8
MZ1P*<@E$0'_2`0]N@@B_8N'+EF@\:K.V94#NVJ3A)1RU*Y`YFYG*!#BJ@"Y4
MS"03`'4!1VWVT';T#0=(TE'$,H0[]F0Z1NA4AW*)3)G\?PG*8X"4W@/@.@'D
MH]-5L@J]:IKO.H&:"BZ::[L4TS+*`U1.8%'`II%$Q@(!A*4!$=!^RSILV**C
MA=)!,HE`RBRA4B%ZS%(3J.<2E+UG.!0W'Q,(![=!^G67P]OX@$0V*8?8&_CL
M'AX:"`*IB!A`V_1N)M@-N&V_V;;_`&#_`#:#BDY06(15%4BR2A2G342,"B:A
M3EZBF3.3<J@&+XAL(Z#BNZ;-457#I9-L@@FHLLNN;R4444B>8JLJJITD3223
M`3&,(@4H`(B(;#H.1'""B95DU2*(G3*L14@]:1DCEZB*%4+N0Q#E\0$!V$/9
MH/T*<I]^D=]AV'P$-AV`=O$`\=AT#J`/O_F$?^8-!#S"";I`=S;`;IV'<"B.
MP"(;>`#H.0"`@`AX@(;A_(.@@;QZ?[0?UZ+G#Y$G>$*JKW5^X`DBDJLH;E#D
M(A2IIF.83BNU,`$3)U*+")"B.Q0ZA$-@`?$=1O\`!7YUC+&V9%1V4K9`XE5=
MB1NW4*H*92K.3%2;',MX)II^<<NYS"`%WWW^W1'T-,S6VJ.^S!.X`0[07(&$
MN;/C&>LGIK_"=&CL>4&W1%+`9'.!LR%L(L#04(]9GL"<HD<TJ[Z.E1,.LQM7
M9X9GVXSE\\9N8!*4H"!@*F0.LH]1%#`'290A]Q`Q3"'[OV^W4:[5B*Q.[]C^
MPO\`UB7^U)H\;]D]'VE8:\U7&7'R#R'>IMA6:72,01%MM=BE5@;QT)7J_3V<
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M6%Y%R+=TD(I%`B@>:4"!;/S^M?.#MW\R>,EFRCSZY)S/;#SWE%#'][MK>.Q(
MCD/`U\G$G`5N'M-Y#%[@'..)*4,DJFY,V3=%9(.4!4,H4BA@S*]RV^6ZL\;(
MR,PIEG(U,Y$Y2MD!CWB\VQ)(5,TMD++UL9.TZVUG"6FN6B'?8OA&9EI^QNO)
M(1I#QRRP+$'H*8+9,]<C\W=O7#/&OBW&95FN:7<:Y@79OCS$\GETL/%59K:3
M,&*^2<ISL/282NC!8/Q>T(H\18%*+IX<R:!G.YE#D"X!'MQWBV5=&2R[W!><
MD]F9TT]\DLB8ORZTPW4(B?51$RIJ-B&IU_\`0<76F;D?]V9R3>56,D4`775.
M)CB%F_'+G3R8X@<^X3M@=PZY1F76F9H-S9>$O,5*OQU-E<L,&AERJ8QR]!Q!
M4:ZADA@=N=N5ZP31([=`0#)C[TB8H;!Q3"=(#AL`B3<-P-L`[?:4>DVV_P!F
M@Q4=TGN-N^#E0Q3CW#](99DYD\I[PUQ5Q@PZX=G:QTG9GJ[1H^NMU6;*D?,Z
M'4!?I*.S)]!W"ABI%,0`443#CCWM^9JLU68V'EKSYY9WC-\PW2D;.K@G)Q^/
MF'J7,.6Y#K0V,\>4>);%_)(58?*1<S*\D\=@0%5MA,)`"2^,5`YOT;/W*#AU
MR'Y'Y(R_@>2Q%3,E<6.2S>$J]8SQ6X^8L\_6[M1[=?(FMEJTY=*DY;L56CQ>
M-,LY9N?-.GXB`!CZ[<WK&Y%\W>YSQ_R_W#N44CC/A3EBNXSQJ-;+B"OV6>;6
MH+'*(3%PF1Q9)?F#Z)CH=)N!&Z+9%50QSF*/X2@&5?%/'3E;CSDEE^M6OEER
M#RUQKO\`QWBDZ/8;K_A@VN.),R_K65CIP*K8:W1H9.0>.*>HV=ME7T:Y314*
M8#=?@&@QB=MZR\R,R=RWN"<?LP\\\^W7$W!#)%%BL>5Q"&Q'`N,@QUN+)2R;
M3*DQ'X[]_F6\='QY&AR,Q8&<&$RW641`N@V0LB4UW?*98*G'W6X8Z>SC`S-K
M=:"[BF-OKJHJ)*%?P3J:B)V+1=@"72(KM%R"4PAT^P0#70[-=YYB\C>3'/6*
MY&\V\S9+KG!GE++X$I%+:0F*:O5K_"LBV9'\XR3^24)&:F7QD62.Q6SIB0%2
M"?;QVT&S*0O00I-]^D-M_9H.6@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&
M@:!H&@:!H&@:!H(#[!W#<-O$/;O^S;[=]!BAY8\0\*\C.3N+6$C'Y,5R6L6L
M7R_7"!S+F2H5RC87Q?84G<=`,JK4KO!4HTUE:X@2)$JS)PX<1Q9)8QA!!+0:
M]EW/W#P3R2%._P`?C9.!IRY#N$C&CD%0Z./@[@6-!PTEC+RA%D$RGQ-&>+!E
MKI3.0JHK;!N(:#)ZQ;W]UV@^ZJUFF%[?X_DK?SU9<,6,DUN;ZW/\%O32Z&"&
M],8N&ZMY4A%[8=;]*%,4[G\O%J*6R/EZ"PKC!G7EMQIF)"*P)7V#F,Y#W_M@
MXZ0R3:L5YK/QZH1[YAJ?JV9V1,4.YN.DV&7:+-5=I*WFP-Y4D8\&40(NBS=I
M"4P7Q7+NG=PBGO<SH1'$EOD>>Q['<F6<SCR#QYDUC,XD'!^2,;4G&63+/,@X
M>-,D5//%2M,M:F,7"D*],SC02:*K@FX5`+9.3'-/E*YR'Q5Y.?X!3>3K3QIS
M+W$*9CZXX[QE>&M:S-AYMA&B,*GG=KCZ0>*301IW<S()(P82*"]A?P*R42L)
MW!``+A,X=UKF=66'*B5Q11L=R$;A/'-:F<1M+EA3D`G<L\,;3!XN>P.;*S#P
M\8E7$JI*S=IG(]U7EI%.2BU(Y--4#."J`8+F^X:RY&/:%V]'N0GCO(F!&/)N
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M=?M\CQ]N_%-"!G<C2M[=H.*%+<5*1=47KN4@3M4V\G+`'NKHJY2IG"OG!SD=
MW">.?%+B1B''_')+(>-E>!]MRY35EZ)<X^]PN3,%6.S2&4L&Y%),344>,LF1
M8IW$M::<&"*ZSU^L*B2Q6I@.%9NV1RE6?<M.7&6<R,K2:Q\Q)#M]PM47J&!L
MMUNG1N0I+CO=7=KI[Q":C)-S`,<<S<:M#3$U)KH)>_I)@X\HZA`$-DT!W`!^
M\`'P_;H(Z#7$YX85Q=#]R3C:6%P$[RE&VOC7W![SE"G,(NUN(S*.5Y^K4>2Q
M?7K5;4$'$3%6BV2<*_95Q1=PDLP.4X,_+Z=A"V&1Y<\D,EV;@+RHME2HT?;L
M5UGFS8JY&U?#_)D]?QLNKPUC'*.,\Z5IS34;F]G*IDXKB&!*"*Z5DBMTR(#[
MV8X:#,OR)NMNM$SVRUK"F?\`P[RCEQE8\LD@F,U#1$M=6''B\7[$E67C+&DT
ME6,1-95CVZC)C+@DH,@T9H."></3H-?3C@YY-EXW]REKDYYG5Z]GN!-OL^-K
M3"KY?@,@QF4QRMFM2MT_/46</S#UPMGCV,1.XJ*Q(IY7&S8@(`3I,<+_`+FA
M8K!9<`<$);#MH2N_)G%S#@]DH<`QUDRU6\[Y3BY"UUF"G8R`D*_.,&M1CWJJ
M<BI:'LM$R1'#"-792!VB"AE!"_7CQ$U^_82YZX[RI*V!MQKKO*CD!5*7*15B
ML=3>M,.Q3&KV2\P]5L]5?1]C8UZMY+<6:,9GC7":B;=N9!$P%(4`#&QR2PWF
M7BIV]<X9$XP8KN7Y7F-*RYILM"LN5,@94MM:K4)$Q,=Q]PHQIV2):[66QL;N
M`(R-SCH]9%9PX5=,`*=-8YB!ZUBIW+N<YO8#R3C6Q2=]LEYR5A#D;8:G5;;-
MQJ_';C/6^,4A5\R<8,H%42:X;2JF8<BJ1SVJ)JG0DCS3Q9R9NFBS%P`5*[C6
M0H>]3?$^N9"A\\\9^3CG*N-\E&EL<N,NY?;X7QACK([62FX&/?8)B);&5BR#
MGIL4D"E&/O,0&/<KKNE4T&1?-"F?(F4S\+COW1.`)'-2MD6C.)L]C)E#K9$=
MR+:LFH<&CR82P<I*I'9M9E.(6EDUV]?,(HR1@!,@+`708_,R>K$J>?#50G($
M.)Q&_<=_X<`UH,IC)I<A@#`IN,HLO*)^J!@!M)+4-&&4#W'W<7H%$4^G0;G6
M-!MXXXQ^.0?*"^C2:H-W!`$P1"W_`)$P_4OD@D(I`E^<^=T](B7;V>&@G0W^
MK_:#^O0QE\P3)C!"2_B=I2-=I-UV<CW3JLT>-G+=)VW>-5+Y`@Y9O&S@JC9R
MT=(&\M1,Y3$.0YBF`0$0TW;_``3%*:\OPNZ_B"NPT^XO.;YS8X>U99[QKFW3
M^:S#B:$:G<NL#3$JN8[ZW5MFB0RBF(9)TL85T2@(P"RO2!?<A**$P\:^:,?R
MXMQ+DT8#=H;-`D$!(;M[VX2B4?PB4<!.=A#;P$!*/\VJ\HUOF.;Y$D<`>ZMM
M@#_L;3[/L]W2#^K4V?1OV1U_9W#^PO\`UB7^U)HSW[)Z/J&]]>4MT3V).0*]
M/.]2=.,.X7C9Q5B=4BI*A)VS';&U]9TBF,5JK"+K)K?ZOEG-U?AWU6)>[VDF
M5/CNV9P29T@K0M?#C)BMRV]T$#(FD7E:9N[$IN&W^\GL*[H5?M!4Q@'09$E#
M)DV,?8-A\#"`?A$=B^'V@(]6WA]^@UL?X@I.RKY6[-*5+<P+.W*]QNF%K#NU
M,I&2K+6<-$H?ECBP1T0Z8RC^'2==)ET6ZZ*QTP$"'*.PZ"F$++77E;WBZIQ2
M[KR]7@;MQ?CVG)?@ABG#K.0B^-F?7A45$Y#*,]+7!P_O5KR)0",3"V@EU$HY
MD=JY.'F'3ZE`V%^6/&/%W,?CQE+C7F2$0G*%E2KOJ])`=,AG<._.3SX2S0ZI
MMCM)NN3"2+QJJ00,55(`'<HF`0U_OX>"IY.RW2[ID/DCDYYF2X<"\BY2X#\=
M591L*;:F4>FOHU:XW)1=4RBTQ=[LU5CX@)%4A5VD#%I-"[@HL)@\C.M@=R'\
M5CP\@;J)RP%?X37DV+FSP/\`<C3LU"Y.=33J-_\`1B_5,T734$1WZ4"@'L#0
M;3Q/!(-B`GL4=BA["^W;;8-!JL_Q,]<7-,=IJZTPAT,QQ7/:EURA.XY+>7,2
M=6@I)ZV;G*45C-DY6"9*&*/@&X^'CH-ARZ<P.)^.+)+TK(/)C`E#M\"HFA-5
M>WY;H5<L$.JX:HO4"2,-,3S-^S,JS<IK%!1,NZ9RF]@Z#6XS1;*_D_\`BCN`
MTS+V"&MF+#<+;+:\`S\=*,Y:I3LO*5[+3D9RJ2K!=>.E"NY%,_0LB<X*&2*`
M"/2&@VTP`!`/PA]@[>W8?`0_>`AH(&.4!`IOMVV^WQ$=@_;[=!J3=O\`)S#5
M[I/?7]*;WC.R`G)^@%N)^04;E!X<7`5^TG@E*U_AU(L0*V23,X!Z#L1,8XD%
M/8.K09Q^VH;E&3$.7TN9,G%RN<T.5&>&TN[K+:>98^-6T+`R2II,7-;,`3*6
M.PKGNWY>583J!U'`YC*=8Z#%[VFQ'_C+=^<-QV_Q6P=X;^'_`,/V+[-!LK"8
M`V`1`-Q``W$/$1WV`/V^&@ULNPR`!RJ[Z^P;?_DAL8^'W[6SQ_ET&R:)@`0`
M1`!$=@\0\1VWV#]NV@CH&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H
M&@:!H&@:"`AN`@/L$-O']N@LRR3S.QGCKD#'<:VE9O\`D++RN/JYEJ>KM`A(
MJ3?5G%]AO1\=1US?,I2<B).>CF5@!91VWAT'[I@P05<K)D3`!,%P&4<HU_$N
M/[5D>?8V>>AZ?'EE)*)H-:EKS;G;8[QNQ`(6K5Y!W,S"Q%'(&.5%,PD2*<YM
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M-;3,)-,%#%(8[23CGB:R8B`")3AN`#N&@FG0-`T#0-!#8/N#[/L^[Q#^8=!'
M0-`T%BKWG;10Y$99XS0^*LV6B\84=87#(\O7:W6G=5@XW/:YT<>SK=TM;V4U
M,1RGNZZL@5JS5<,D6RIS)B4HCH+UPE8\$O.]]:J)=)S^:FX042`I#BFH('*I
MXIIJE$HF]A1#81W#02'F"<QG6\:7"ZY;&$3QU0(9QD*T2,^V(ZCH:.I)36;\
M^`ARF.#R&/%@X;BG_?`LF7H_&(!H+68/N*<=9'+%9PC(N[E`9(L<MC6LOHN2
MJCM9E3;_`)CQQ+Y;QGC:YR;`[Q*%NUJQU!K/R(`"C1`0*@JX36,1,P>_7^;N
M";QAK(F?:?&9)M59Q;?,FXJMD;&XMLB5^96O$[IZAD2+)6I5G'2+>/@3QKA1
M9RN9NT.5$=CB8Q"G#V..G)+`.8F=:I^)&#B&A;!A:B9^QY!R-4<5!O:L.Y14
M>#'6J+KDFV8R+,S6P`LTF&CQJ@Z:/5DSJE,1PFH8*=LNY=Q*=6O(]53ML^D?
M&L-GB7D+$K3Y4E6L8\8Y2#@LZQ%0ETTC#,SF.YNRL6;AL9-`SI9P4&@N``Q@
M#Q'G<?Q-$8WQSD-7!/*UM*YON<U6L<XE3P%*DS;=?R%E'JR5T#'Q)).084Q)
MH]0_]Y2"K;<@EW*`=.X7IY#R94\5XXLF4;W(*5RIU*`4L$XLY1$[UND"2948
MTC5)511U-.GBQ&K=LF8QEW:A$R=1C!H+-+-W*,.TZ<Q[6+)BGDZL[R*;%K",
ML=*P'?,CXPC[)E_W`*G5'F8*0PE\<KSJ9I-(KT&DBNDS$3"=0`(<2A4?(?.'
M"N,W&>E)QW+RL;QV9TM*^N:@V;VB9?6^^29(J"QS4:?%/EK-9;<+QXR24*BV
M!`KMZ1J"@N$UR)!7G#>3$\P8[J^16])R)CEK:&:C]O3\L5=2F9`B6H.7#=M^
MH:NJ^?JPB[Y-#STT55/.\A0AC%*)M@"J1_\`5_MA_7HZKOT?,2O?_P#4*K_^
MUBK?_7-=U&NO9'1]-F<AHJ?B9."G(]I,0DVP>Q,S$2*"+J.E(J1;*-)"/D&;
MDAV[QB[:+'3524`2'3,("`@.JQ-.CBGWI:YRXX*]P+A#GAW!U;D[A[CMRNK>
M-739)K#P6;<74FI7J+C#0;-(J#1E>J3!1J:,BP1(4KIJD5T@4?[XB9W3NCDT
M(8[_`+*V_P"YM/\`9`'_`#ZFSZ5_KCJ[X%`YTB".P&70+O\`VEDP_KT9[]D]
M'V=;!ARB9VXP+8.R=$)6''63<+M*!<89;H`'\%/U%M%O/+4.FH"+M!)3S$5-
MO[M4A3;;@&JQ,$O"/(6:^RI#27"'FM2<H7WAW3[%.R'$CF_C'']KRK4X/'4[
M)NI1/%F?Z_1&,_;,<3U=?NE#-'XQZD:L54Y`5*F4B@A='R8[J=;RQCAYB3ML
ML<G<EN2>3W432JS8<9XLOJ%#PBRL4FSCI[+60\A7*L05(A&U'@UW#YNS4<J.
MG+M%-,4@*)C`%AW>]S4VL')'MFU&C8TY'Y<<\/>9]*S%R'LU!X[Y?MD!5:9!
MQ\.@Z>EL<131@+7-ODW)G(-8=9X(`DH4W08.G07%=X'CS<^7W'GC_P!QG@:S
ML3SE=PMMP9NPDBXJ%HI]PR5C]I("&1,8/JC:X:`M@N))I'F<M8YTU24=&360
M3((N@$0R(<?.XQCS+O&)'D3D3&V>L$O*Y$5,N4<;9!P!F1C<:Q;[`BFBI!5:
M%1I;J6R+'FERJ)MWL*B]3\@4SK@B)A``Q)?P\^2WE%9<NL-Y*Q+R"Q/<\S\U
MLY9\Q:7*&!,K4Z`MF.+JDP?Q[Y.V2E50K$1)((0ZOFLWSQNX`YBE(501V`+H
M>\-P$S=F.W\:.?O"IM%O^:G!VT?J*IT67>IQ##.F,7+Q-]9\5KRYU46S25<)
MF<^X"L<J"J;URB)BG4(.@KCB_O0\-+146A\MR>2^-.96#1NVO'';,.&\LQF5
MZM:03*5_7HB)C*5(HW\@/>HC-U"'>)/$^@X`43=!0I15<"Y,[BO-_"_-C.V-
M+9AWBSP[0G7_``]P[DV.5@LHY5RY9R(M9;D=D:C.%%'6.Z]"1K5)"KQ#\2S"
MPE]\=(MP$B0A=YF+M.=MSD)DFSYBS;PSP9DW*%U<,7=KO%MJ2<E8)YQ&L&T6
MQ5D':BY15,VCV:2)0V`.A,`$/#062]RSM6RUPI?$S-';PAJ7B;E+VZY%G)\9
MZ7TIP6/[CCB/5:*3&!Y5??RHF)E&R!B1RBAP005763.)2+F4(%:,8=YKC&O6
MV<9RHBLG\*,[139)K?,)YVQ1DEB]B9Y!,"21:7<8*J3%.R-7%')3>XOHMVL+
MA$2"*93#TZ#K86YXW+.W(3,&;`H.<<8]O+!V$6<36,B7[$5TK2W(?+UJN,>X
MEKA0L<O*Z?+<C5:+6(L&3-8L4G[XM)J*`4Q0*!0Q,]LOE$TPEW!>[9F3+6`N
M75(PSRSS77,B82R6[XH9\EX6PP5/1L42L5_&P6/I.<A'<RVDT7K,KIJ0#H&V
M.)#_`(-!F%<]RN$R'G[%E`PM4LNML/5RM9.RYRES7DWC?FV@TZDX[HU56&!I
MM>>WREU9Y*WVU6V4:+@DR;/#)1K%?I*=10H%#";V\^954PWW6^ZIFFY8>Y3I
M8`Y7W:DS>'LR0W%7D!8JU-!0F[R+=JNV,-CYW88R,F4)$SADX69@54B8]73N
M3J#,A9NZS2+/F_$]-Q%7<Q1^'X5E>\G<H<W9&XNY^IM,I>,ZC6UFD#4J^ZN-
M%KDG+7VZW^:C4T$V#-^H1F@OLF8QP$@8=NS[S-JN`.47=3G\OX7Y7T_'G*+E
MO/9TPSD@G%#D%8*W9*BK)VMFF1VA7<>2LS"/'#!VU=(E<M2`=-4=Q*8`*(9S
M<4=P)3E!R]H^&^/5%RLCAJK8SON1L[Y4RI@#+.*85Y)BXK]>Q=CNAR.3ZU3G
M#Z?=2DF]DY(Z39<J;-@5,.D5NH`RC:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:
M!H&@:!H&@:!H&@:!H&@@(@`"(^P`W'^0-!B/YP=OFZ<O\R8KR*WG<741_AR\
MX?O6(<[Q,5:H7DMAL*E=6TYF"D5N:A%$H>\4+-5>9$BUH^7<MV3'WMPN9NZ,
M"72&._\`X)?*=?'6=<:.,_81",R'QFL''.E3"#/+!)&.2=\QK-R?K-VL[8[P
M4"R\+7+$%=!)FH`$3:IBF<$=T]!5/*/9PS!:[KF2S0=[P8O6LI\QISDS-8_F
MF^7JY&Y+JM]P-"8ALV-\I6;&\O!68JN-IQBZL%1>L%SD*[>*`NDD?98@9(.3
M_%#(F9`X,IT.PT:%8\4.16,\X3Y+4>WKK6J,Q[2+-32UJON$!EWS=W(IV4ZY
M74@X<J!Y)05\T3G/H,9V:.QE;\W9FY39$GL[UVJ^I9KR0CK9=:Q7Y@EPO%.R
MM!T(N$L99$I9EV^/T(?CI;:*U>HS<:H29LC1$K=YT>8JIH)KG>T#FB6NMCY(
MM<PXR9<G+WD#/\Q:&ZL)<'.'(VD9XXFU3BFM#5UN<2652:J4=18^Q).%D4T7
MCLZ[(_E(]"P!F?XQX5B.-O'G"?'J!DGLS"X1Q70L6QLU))^3(33:D5F,KP3#
MM`IU$D%Y4[$5S)D.<B8J=!1$"@(A770-`T#0-`T#0-`T&&>_=M"SY"Y8<V^3
M%AD<124CG;$^*ZIQ]5?$R3^H,/Y!Q!3[G5Z_:;.2!FJ^A.0<RYN"JKUJR717
M(DCY:9Q,H8P!8Y%=E?E4SI]08/\`+?&EU=\>\L[3R?K-A-"9+3KLO7<@,*/&
MW_C+9Z8P;14&?!MI3@I!PNT;$`XO3-7)2$5*Y,N&2Z3X07F7X0<N^-4G)8WK
MMLS[;L[72JO,?*9"_1\4\R)8?U-46$Y^O['8IHBZ4BT0;RX,3,XKR3&]S:-B
M")`"W57MK9;R/SMQMW`INVU?'5TB[7A6VK-R,Y4N3:CCBEX>G<?Y&XI/F$,J
MKC>]4>[W">5ED[0].>:C"J'2;$,04A(%4\><)\VXWP'FS#-FI?&[D'$<@>7.
M>LW6RJVZR9`J]/84#.,G-V1*)=)?I:95LDS59QPT26;*)H-7S/S5"F27(F!@
M[_"'A!DCC1D#"["WWF<R!7N,?#=QQM@[Y9'SAS-92M>2<IQ^5;<]:D>/Y25:
MT#%L968N!@"/EC.O=S')N;R1.8*&XJ[3UMQ?RFS9R5GYG&&76V86/)B-RU0G
M45(0\;RMKV:;G6;%BVGYGKLW%3F-J.A@>!A%(I-]"-'*UE2!)203!4I^L)5G
M>SFRE^+>5^-J>/<'J+YCR[E;*..)U>4M`UKMZCD)I6(YBWXJ&_*"7=:8@7%=
M_.T_<75:C%K`H83)HL@*CH+ZLT<`W>5\966K+\D.0TU/_IZ.;TIA;,@Q2./H
M&X5ZA2%+B)]S!15#</WK5PXD32KM-VJ_7/(E(NBHFHFD<@>9PUX79+P/BWB9
MAO+%^CKY7.(V$(NJUQW$O)$26K,"K1_6%KVZ:/X]@#*'I-#_`-SKS99-95NM
M*.E#G.=%!00MNKW:M>8TY`\C\DK-*KR=PGFG!N-,0Q_'_/5F/,I34O3LAVC(
M4C=,HSTKCF8CITY;%;W;]J8J#B12>%,J*RRJP"D%_?`3BL]X9\9ZA@5[;%;:
M-?GKW8FI474R\KE-87FZ3EP88RH2EB<O;"7'>-VLR2(A0?*G=>XM2"<""/04
M+S3_`.K_`&P_KT=5WZ/F06TI#_Q1:B1B`<%.ZI71_%["F3MT6L!@]OVHE_FU
M-VJ/K_S^'TX3&Z?L$=]]@#Q'P`3?T[:K&^/?QOK,;:>Y]AZF6>%+-P=FYWQE
M0L]:>(N"IR\%/9J?0=GKD@@F<BXMI>)>.&SD@]/F(BH00'8=1K\7UPO7[V79
M[O';*S2\N-*9R-FX?Y7LL@IBBZ%1.M_AY*O%%WP8>NJR91*TD8I`#$AWJG2G
M*L42AO[RDL4QU6WRC]6#]+_IVW_>FG_M"6AY.R7VQ:`H5.@T<3;[?HVM#X`)
MAV+"LQ'8I0$QA^X``1$?9JL3PL?9FQWE2DO\AT*;5L%2C92W0CJ20B9AJJ$M
M1)>2@+6P3CG[%I)+.8F:AW34Q2)&$ZJ)@)U>&X2[C+DIA3,S>D/<6WAE=XW(
MU&D,CTV6@V,JM$S%2B9I&N2K\)-1BDR9/8R?<%9N&+@Z3Y%QN0Z("4VP>!*\
MN,#0N4$\-2%MDT<BJO?<4X0E)O*[8RI7\!$KKA/-ZXK7C1[.7M4<U<.@="W;
MN'B9%#E$?`)FR-R'Q5BFSP5,NDS+M+59*U9+C"P<14;;:7SVL4]S%-+3,E)5
MX28(DS@5IQG[R)S%,0K@@["`[Z#VLEYGQWB&`@+-?9EU%1%JLT!3:XJS@YV>
M=3%HM1S)UR%91L#'24B=[,*D$B)12`!/L41`1`!#MP&7<=6O&:&8:K9V=EQN
MZK[ZTM;1!(O)-JZ@XPCH\@[;-6K921659F8K)J(%1%P15(R8DZRB4`\;&^?,
M1Y@"MK8QN;&ZQMQQS#99JTY!-I!U7IV@S[U2/BIV/GO="Q2IEWJ)TCM15!XB
M<A@42()3;!-*N1*4GD%#%AK+$AD5>HN+^A3A=)!.J4IK,MZZZLI&AA`XQ24X
MZ3:F4]@*FV^_04GR+RUP/B>XLJ#?+=(P]KD0`648WI=XG2.-HEY/K%)(5^N2
MD8"K.!CUGS@@K`=NU3%10"E\=!4>XY<H-!E\<P-LFSQ4OEFV$H]`9_EDJ]_/
MK0>%E+&$65S'LG31B8(2%=.14<J(I`FB;\6_AH//R7G#&>(EH5G>[">.DK$W
MG'T+#1T1,V*<D(NKLTI"T3*,+76$I*!"5IBNFJ^>&2*W;%4(!S@8Y`,$+;G'
M%%&Q"^S[9[O#,L,QE8:7=[D-N9>7KJ%.?)-W#>T>\Q"#]52#]S=D7.X(0Q$V
MXBH80(4P@'LU/*=%O4Y8Z]4ILDX_JC*K24NJR:O#17Y==8?]059_&39VY(>;
M9S$.(+IJ,EUR@00ZA`1`-!WHK(=*G+I:\=1-DBG]XHL=6Y:WUANZ3/+UZ,N"
M<FK5WTFSW\U!M.)P[H6YMMC^0;V;:#H?XIT3_$X^&PG"CDI.EDR(>L>XR/GE
MI2DR>O%L`OO=/RH&@S28M^CS_.ZP_P!#;QT%0#'`FPCOL)@+O]PC[!'[@T%/
MH#*M$M%WOF-X*;]^NN,2ULUZ@OR^3;JU\MO8JR=:,X>.F:$:Z"7CT#K)>[K+
M#T%$3;:"3(KDOA"<EY^O1-]CY"PU3*K/"-I@6;.5<3%:RE)0R5BC*I/1R+`[
MJ)6E(%<CQLZ7*1BX;F`Y%C!H/8R3G;&&)',%'WJPJQ\Q9F\X^@J_%PLY:+')
MQE89IR%EF6L!5XV8EC0E?9+$4>/!1!NAYA"F/U'(4P5!K%EA+E7H2UUI^G*U
MZR1,=.P<FB11-&1B99HD^CWJ*:Y$G!$W+58IP!0A#AOL8`$!``]W0-`T#0-`
MT#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-!`?8.^^VP[[;[_NV\=]!B
MWR=R,R_DKN"/.`6(KBRPHC3.)33E-<,JKU:/N-IGWUGR6]QO2Z94(&PF"OEK
M<.[C5G]B=G*JZ4*JW:(&;BJ9<`QL\:N\?=[9DFMY#Y06*#QEA7&G%_EV?.\)
M4*\XE:Q9LX<;.858XYQ^0,<+>1*W*0ALA)2!4XN%2<.`(_>&0ZUA3\S07-<6
M^Z7%I9+R_C?DJ^R$QMV1.?V;L!<9:7)4")@YF!I6.J+B2Q-:5956+Y&&+88L
M]X.JFW%Z\F))(YU$452H+>6%4L?][CA=D9W2D(F,Y`13.^O<1)0DW8\,3D9!
M)0^=,G6/#6-+;*R9'CE*/K$]DRK.HD5S;K(..@5$BIB)RA/%Y[O/$_'LKD6O
M2<3G.6L^.+UAC'K^JUW$,Y*6:PSF?+W9L:XT/5H/WA!^^:S5TJ3UGT."-70=
M*2A43I+HG4"H7<0Y'9!P7VYN3'*?#2@5G(F+<#3^7:@TO%=3>$8RT'%)S9:_
M<:P[<$,BOT];-^U\TJS=8#E`0.3;06!UOEYRS#D9V]Z,ZRG,R..^5&8LETF^
M1&1N.;'&5Q:1N.>*\?GI<M95<NB*N(2:LC@&S653;EZF`K$#K42*J(9(.?.;
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M(CN(Z#]-`T#0-!BWR?W?N'^',Y6?COD-;*->R95+XCCA]'/,?KHL'UCDL9R^
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M>1I2E=P@C+-ER.)#)4^KD.&0;MD6YV8.7I4E7*1P,4`H_>^\EP^Q_7&%BFF6
M;WJ@R7)F%MM=@L2R\I9<:3G#]&'<\@(?(,<1VFE$/J2PGV;H`05=D?-7!5FQ
ME2#U`%X/&'EOB7EE'9*?8M)<F3C$U^3QS=H:]5-_4)N.G'=0J^0(5VBP?&4%
MU"V.E72,DF3@IO[QNZ*!RIJ`8A0N@T'`_ATB/_GET=5WZ/EM<BLKTG!/\1WD
M7-.2I%6&QYBSN2M;O=)ENT6D5XBN0UIBSRTJ#!IUNG+>-:B994J9#G\LANDH
MCL`S=KCZ\?U;VH]][M"JD*;UX8;(!B@<HB-O14Z5"CTCTGJQ5"CTC]P"&JQ,
M8]8RM_#`5#F7(<[H#/>#&G()[-2%P1D#3^1U:7$WN5*L27R#!T56$&MQ]SDO
M>53JNR)?A64.J0A%3&.)W\[17XQP7K9][K_8KY/8@O>"LW<P,"7O&61H5Q!V
MBO2I;6<%D%@$[=_'N"U@'$;-13DA7+)VB)5FKA,JA!`P:.J3>9S&SYP',C#&
M$L$<@K)2>-_(>E\GL'*2#.7QODZIN'PR!JZ^?B"-=O$>^CXY2/ND"*?E.3$*
M9NZ(!5D_!38D>]LSXYSI.'V'*"!OT%1C%#J$M,K(@&X`41_*&(@`_A,.YNGP
M$/9]VJQK>N+F$KUA7`,]C*UNJ[(6EW>,\VEBZ@)"54ACMLJ9.O%_@FJ[MY%-
M7J3B/;6E-!T<J)P*JD84^H!`-!2CB]PUL/'O+\CD)I8XIC2KIAN+B[;B2(][
MD*_6,]+RE<6R!D.A2CIE&*,ZYDEM7FSJ18BW1*,LB=X4A3N5NH*XRN'[C(<O
M*!G)!>N%H-8P#DG%4I&JN9!.RKV&YWS'UNCI!HP+&&BCQ#-K2E$E3'<D7\UP
M40*8`WT%*>4'&K(&6LTXMR95&U;D(>@8GS+2G45)Y)O>-99Y9<C3&-YBOORR
M])A9-=Q7H97'Y@?-E3![R1T!2E$"FW":N7W'J]\D\5XXH,3:DZE+PF7<67VU
MVB`GYVI3,=%4]VN\GW>/9J)8OG\?;DEEO,B3*@DD51,HJG*&X"'JX+Q%D+%/
M%*)PA(ML?'NU1HMCH\0]IA9>#IMC7!&5;0-L>MW;%W)U^0M`NTY":3*5YY4F
MNX%)18@E$0D3BOQ,F^-^0;O/1<\P;8UO5'IZK/$L<59Q#8NRPH^E)++KNC2!
MVK$#4+(,XZ;RB;$4$`9RIWJJ9")NNA,)=MW&/-$OR>H7**(LU>;6FIY8D:\Z
MK3J3$:W)\4YVBC6IF!*X2I@6%+(![2DUGDV2CTT.#Y'<#`.XZ"N&8L172[9Z
MXJY)KI*X6LX7M.4IR\$E9!XTF'[.\8MG<?QB$`T;1KQL_<-G4L"RX.E4"`@G
ML43".P!^F>,47?)%\XL6&KC`)16&LYGR7<PF9%\S?+P!L89"HH,H%!G'/D'D
MK[Y=DE^A=1!+RD#!U@(AH/!S)AS)3K/6/^0V*OT=,V"L8>RGAF5J5[DY6$B5
MHZ_S%,M$3:(V5BH>>43=0T]2TTWK4Z`>^,5S`10BB9=P\*L\8Y_&7""L<6:P
M[A+U.U;'M?IIWUL.M#UFQK(RC.0L@NT4F<VLRA'@'=IMF8HKE(W\M$_X=Q`.
MUQ+XLR?%]_FF":V\UBQ5:+7`2&%*NZ27-*XGQ\Q@3(CBH\BH.\I7JM/O'A81
M4QC*MXA5!J81!N4=!3N@<8LU4_E/"\F75F@G3K($=EBH9_J9I1)6+)37\Y&S
M.#C41RA3HZ5F):BEABMG)95T*:+>1>%;&-U!N$_WW&&>6G*=UG3&$5C66AWW
M'B(PR@UN=IGX5W&S2>3'=S>V%>-B:M+I2<6TBG0ID;E=MEEG`;"8A/QZ"Y>B
M2]]E(N35O]<B:W*MK;9XV,;0DHO+-9&J,IATVJE@65<LV*K*0FX<B3APTV4!
MJJ<2`=0H`;04=Q?B>\5'D7R>RI-#7ST_,)<,%I[=@_?.;`W''-.D*U,!/,5X
MQLQ9IOG3T%6_E.%A*4H]8`(Z"@9N'%Q4Y(P/).(GH6BSR&8K`ZR=`1"SN9CL
MU84+#2BF-TK.52,B@B\D8YMTD=>-=$!UY,<[>,SK*)*D\H*J91PSDXG)K'O)
M7%Z-0L3J(P[=,&6ZEW.:DZX@,!9[76KM$6ZLS<=`V,Q)2)FJZ*#YDLW*5\S6
M+T+$42+U!<K0AMY8(B-VB*K#3+=T^;)M::\D'D#^4MGJZ4*L@:4C8IVU<.8X
M"*+-O*$C90PIE44`.H0G?0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T
M#0-`T#0-`T%NN5N*F$LR7BHY1MU9D&>4:+!3]4JV3*;9[+1+[&T^U^6:RTXU
MGJ,K$2;^J32J)%5F#DZS8'"95B%(J4IP"B=B[8?!:TPC&KR_'ZL'JL9A"?XZ
ML*LSD;)'5]MB6T6YID"=@"1C"9;H#)2%[8(31Y8V\O\`FB)7/O/G;G$/+B.U
MIPIAW"#D,9V"843RK'YO=%L^5,IVE*6RU#C!*PN0)E*?N$BG*6>'>UEBY;.E
M0,JFX;E/N(B;<.A"]I[@C76<"PA\,N&36L1^-(J!2)D+)!RQT=A[),IF#&C1
M+S;8<3IU+)DTZF&W7U&%TN;K$Y!Z-!YC;M(<#8NSN[A#X@FHF??7NKY.=N(S
M*64FS=S=Z1D^9S%3)Q5A^L3,%'%5R18WTFP(*?E-U72A"E!(W1H*IQO`O`BO
M'G+O%ZXP\W=</YWN^2[UE"KR-BG8=E-.LL6AQ:K;7&'Y%(L7T)4'+Y<2E8-G
M!4Q(93J$14/N$QY`X0<=\G/L#2UQKEJ>SG&-G(-,&V!CDO(D'.T$9:O!491[
M'RT+9V#U[*2%7WCUG+L[A8[4QB";81T';L/$#%$]CRCXG9RN4ZGCNDQ5MKOZ
M:J&5KM"HW2O7E@ZC;9#Y&D!E74Q=D)<K]=<R[QP9ZB[5.NDLFH83:#G9.%?&
M:VJ\?1EL6PZ3+BN[0=8&@X=U*0-;H)FU6=T=!%I7HA\SB)1FG39!Q%^0^1<H
MBS<*DZ?QF$0DBB]NSB-B^*D86AXP_3L3*M:/`N&*5DLTB@A0,<7%[D&GXDBR
MS$K)#"8CB+9(N705UGY,:?SSIF3%(0(`7/&QO5CY-3RVX;O'-S:TPU`C'3EX
MNNPAZX[F4YZ53B(TW^Z,'D[)(-O?G!"@LX39-R'-T)%``J#H&@:!H&@M:R7P
MGXJYCR&\ROD["-)N>1'Z&*6SJV3+%5:641PC>G>2<7$\XBZ92_I.YOE7B(@`
M&4ZO+5%1(`(`0L?";BK;<MKYWL6$:3*Y>=7S%^3G%^<L5AGU;UAB`L%7QE8C
M.2N"E!Y4X*TOFZ``4"'*L`JE.)$Q*$EVGMR\*KC.W*U36`JC^K+],9@L-HML
M6K,P5I>S^>J'#XTRO--K%#2;&7BY.V4R`:-%%FJR)T!2\U`4UC'4,$LVCM?\
M++<GE!M*8NF$(S--?I]>RI!P^3LH0M=O)*(R@(NM3U@KT9<&T,^N;2)J\>T5
MFS(?FKINU(5==3Q$0[TSPFH66L[Y.RER`I.,,BUR:X]K\4Z!$.(*9?6)S@RU
M*LIS*,+E":F72J,S(V2TMB%:^Y%1!JR2,?K%==4P!6'#'$?CY@.*L,5CK'C!
M`UNEV4[;)FT/92]6:S2D568RE0[J;LMS>SLV^_)J="M(MJ0R_0@Q;D2*&W5U
M!02&[6/"2MQ5(A:WBZPUQAC"ZS5XQ<6`RYE^'<XQ<V4KE.S5?';Z/O3=[3,<
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ML-=J$%08>46&?E9,&KAI3JQ',/[CRBG19I=0"8O4(5^T'$Y1,```[#N`[^/A
MMXA[!#?Q_G#18F(G5KS<B_X:'M_\GL\Y<Y$Y%M/(EO>\T7F8R!;&];R-$1E?
M0FYLR1G:4-'+5%ZJRCRBD'0F9500\?Q#OIH]?=,1B(T49_REG;)^+N4OU5@O
MD;1XG^4M[9/Q?RE^JL%\C:!_E+>V5]EOY2?ORK!C_P#8X::.Z7FG!`?X2WMF
M^`EN/*0IB'34(;_%2#$`.F<JA!$`I(")>HOB&X;AIH[GS3:)KB-6S="12$%#
MQ4*U455:Q$:QBVIUS=:YFT>U2:("L8``IUA21`3&``ZC?8&CQ>IH&@:!H&@:
M!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:
M!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:
M#@H(@7<#=([AXCMMXCMMX[>T?VAH*`3G)W#=9F92O3=@L+67AGJS"0;(8XR9
M)HHN4=NM-*0BZ:^CGA`W_P"D15.0?L'0>7ZN<#_%%F^E66_D+0/5S@?XHLWT
MJRW\A:!ZN<#_`!19OI5EOY"T#U<X'^*+-]*LM_(6@>KG`_Q19OI5EOY"T#U<
MX'^*+-]*LM_(6@>KG`_Q19OI5EOY"T#U<X'^*+-]*LM_(6@>KG`_Q19OI5EO
MY"T#U<X'^*+-]*LM_(6@>KG`_P`46;Z59;^0M`]7.!_BBS?2K+?R%H'JYP/\
M46;Z59;^0M`]7.!_BBS?2K+?R%H'JYP/\46;Z59;^0M`]7.!_BBS?2K+?R%H
M'JYP/\46;Z59;^0M`]7.!_BBS?2K+?R%H'JYP/\`%%F^E66_D+0/5S@?XHLW
MTJRW\A:!ZN<#_%%F^E66_D+0/5S@?XHLWTJRW\A:!ZN<#_%%F^E66_D+0/5S
M@?XHLWTJRW\A:!ZN<#_%%F^E66_D+0/5S@?XHLWTJRW\A:!ZN<#_`!19OI5E
MOY"T#U<X'^*+-]*LM_(6@>KG`_Q19OI5EOY"T#U<X'^*+-]*LM_(6@>KG`_Q
M19OI5EOY"T#U<X'^*+-]*LM_(6@>KG`_Q19OI5EOY"T#U<X'^*+-]*LM_(6@
M>KG`_P`46;Z59;^0M`]7.!_BBS?2K+?R%H'JYP/\46;Z59;^0M`]7.!_BBS?
M2K+?R%H'JYP/\46;Z59;^0M`]7.!_BBS?2K+?R%H'JYP/\46;Z59;^0M`]7.
M!_BBS?2K+?R%H'JYP/\`%%F^E66_D+0/5S@?XHLWTJRW\A:!ZN<#_%%F^E66
M_D+0/5S@?XHLWTJRW\A:!ZN<#_%%F^E66_D+0/5S@?XHLWTJRW\A:!ZN<#_%
M%F^E66_D+0/5S@?XHLWTJRW\A:!ZN<#_`!19OI5EOY"T#U<X'^*+-]*LM_(6
M@>KG`_Q19OI5EOY"T#U<X'^*+-]*LM_(6@>KG`_Q19OI5EOY"T#U<X'^*+-]
M*LM_(6@>KG`_Q19OI5EOY"T#U<X'^*+-]*LM_(6@>KG`_P`46;Z59;^0M`]7
M.!_BBS?2K+?R%H'JYP/\46;Z59;^0M`]7.!_BBS?2K+?R%H'JYP/\46;Z59;
M^0M`]7.!_BBS?2K+?R%H'JYP/\46;Z59;^0M`]7.!_BBS?2K+?R%H'JYP/\`
M%%F^E66_D+0/5S@?XHLWTJRW\A:!ZN<#_%%F^E66_D+0/5S@?XHLWTJRW\A:
M!ZN<#_%%F^E66_D+0/5S@?XHLWTJRW\A:!ZN<#_%%F^E66_D+0/5S@?XHLWT
MJRW\A:!ZN<#_`!19OI5EOY"T#U<X'^*+-]*LM_(6@>KG`_Q19OI5EOY"T#U<
MX'^*+-]*LM_(6@>KG`_Q19OI5EOY"T#U<X'^*+-]*LM_(6@>KG`_Q19OI5EO
MY"T#U<X'^*+-]*LM_(6@]:"Y.8;L\S&5V$L-@<R\R\1CXY!QCG)<8@JZ7'9,
MBLA+4YA&LR#MXG663('VCH*_CML.^VWV[^S]^^@!ML&WL^S[MOV?LT$=`T#0
M-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0
M-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0-`T#0
<-`T#0-`T#0-!`=MAWVVV'??V;?;OOX;;:#__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
